Developing aptamers (DNA antibodies) for pharmacogenetic biomarkers

Overview

This project arises from our work on pharmacogenetics, where we seek to understand how natural variation in genes for drug metabolising enzymes and transporter proteins involved in metabolism and distribution of drugs in the body impacts drug responses and risks of adverse reactions.

To effectively identify genetic variants that impact such genes, to guide drug prescribing, usually requires lab-based DNA sequencing or genotyping methods. We see a need for rapid assays that can be deployed near to the patient, in a point-of-care setting, which do not dependend on lab-based methods. Such tests should identify the phenotypic status of a patient, rather than their genotype, and could be used to guide rapid decision making in clinical settings.

To achieve this we propose to use aptamer technology, in which “DNA antibodies” are developed to specific biomarkers of pharmacogenes action. Aptamers are generated using a method called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). The project will involve establishing this method for one or more specific targets, and attempting to develop aptamers that bind specifically to these targets. This project would provide proof of principle data towards developing such tests.

Preferred student expertise: A major in genetics, chemistry, or pharmacology, and an interest in development of commercial products for use in healthcare settings.

Useful information

• Graduate research at the University of Otago
• Scholarships at the University of Otago